Bruno Strigini

Background

About Bruno Strigini

Bruno Strigini is an active investor, advisor and board member in a number of companies in Europe and the Americas. He is Chairman of the board of Owkin, a leading AI and machine learning company specializing in Healthcare; Partner at OneHealth Partners, a boutique firm specializing in Fundraising/Corporate finance/Investment banking; and the founder of ARVIC AG, a Healthcare consulting and investment company based in Basel, Switzerland. He previously served as CEO of Novartis Oncology, where he oversaw more than associates in 85 countries working to transform cancer care and address some of society’s most challenging healthcare issues through science-based innovation. Prior to Novartis, he was president of Europe/Canada at Merck & Co. He previously worked at Schering-Plough, UCB Celltech and SmithKline Beecham where his roles included president of international operations, president of Japan and Asia-Pacific, head of global marketing and business development, and managing director positions. Bruno holds a Master of Business Administration from IMD Lausanne, Switzerland, a PharmD from the University of Montpellier, France, and a Master’s degree in microbiology from Heriot-Watt University, United Kingdom. He is an elected member of the French academy of Pharmacy, and in 2014 he was awarded an honorary doctorate from UIMP in Spain.